techMARK (TASX)

(Sharecast News) - Drugmaker GSK said on Tuesday that it will move its mRNA seasonal flu vaccine candidate into Phase III after reporting positive Phase II results at the OPTIONS XIII influenza conference.

• Read full story

(Sharecast News) - Peel Hunt upgraded Computacenter to 'buy' from 'add' on Thursday and hiked the price target to 6,000p from 4,400p as it said there was "more to come".

• Read full story

(Sharecast News) - Drugmaker GSK notched two major regulatory milestones on Monday, with Japan granting the first global approval for its hepatitis B therapy Hibsago and US regulators accepting a priority review for Jemperli in previously untreated locally advanced rectal cancer.

• Read full story

Smith & Nephew CFO John Rogers to step down	19-Aug-2026
Deutsche Bank downgrades Oxford Biomedica after ...	18-Aug-2026
RBC Capital starts coverage of BAE Systems at 's...	11-Aug-2026
Oxford Biomedica shares tank after FY sales, mar...	07-Aug-2026
Smith & Nephew lifts H1 profits, lowers FY reven...	04-Aug-2026
BAE Systems upgrades full-year guidance as H1 pr...	30-Jul-2026
Sage reiterates full-year outlook as revenue grows	29-Jul-2026
GSK launches £2bn cost savings drive, confirms ...	28-Jul-2026
Ofcom proposes blocking new Openreach discount s...	28-Jul-2026
Vodafone sees earnings at top end after strong Q1	27-Jul-2026
Renishaw to beat own guidance after record fourt...	24-Jul-2026
BT makes 'solid start' to FY27, adjusted revenue...	23-Jul-2026
Dialight sees FY profit ahead of its expectations	22-Jul-2026
Berenberg upgrades Computacenter to 'buy'	20-Jul-2026
GSK secures EMA review for single‑dose Bex...	20-Jul-2026
GSK shares fall as cough drug development axed	17-Jul-2026
Oxford Biomedica inks service deal with Plowshar...	16-Jul-2026